Clinical aspects of pharmacogenetics of pain and co-morbidities of emotional distress

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue SUPPL.1, 2010, Pages 27-30

  Kamen, Barton A ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

Cancer pain; Co morbidity; Depression; Drug choice; Drug metabolism

Indexed keywords

CYTOCHROME P450 2D6; NARCOTIC ANALGESIC AGENT;

GENETIC POLYMORPHISM; GENETICS; HUMAN; MENTAL STRESS; PAIN; PHARMACOGENETICS; QUALITY OF LIFE;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; HUMANS; PAIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL;

EID: 84900850838     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bair MJ, Robinson RL, Eckert GJ, et al (2004). Impact of pain on depression treatment response in primary care. Psychosom Med, 6, 617-22.
2. Bair MJ, Robinson RL, Katon W, Kroenke K (2003). Depression and pain comorbidity: a literature review. Arch Intern Med, 163, 2433-45.
3. Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R (2003). Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer, 98, 1643-8.
4. Govoni S, Regazzi M, Ranzani GN (2008). Pain and the pharmacogenetics at the fuzzy border between pain and physiopathology and pain treatment. Eur J Pain Suppl, 2, 5-12.
5. Holmes MV, Shah T, Vickery C, et al (2009). Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS ONE, 4.
6. Kamen BA, Saletsky R (2000). Pain: Above All, Do No Harm, or Make Sure the Result is Worthy of the Suffering. Pediatric Hematol Oncol, 17, 195-7.
7. Laird BJ, Boyd AC, Colvin LA, Fallon MT (2009). Are cancer pain and depression interdependent? A systematic review. Psychooncology, 8, 459-64.
8. Reich M (2008). Depression and cancer: recent data on clinical issues, research challenges and treatment approaches. Curr Opin Oncol, 20, 353-9.
9. Reyes-Gibby CC, Wu X, Spitz M, et al (2008). Molecular epidemiology, cancer-related symptoms, and cytokines pathway. Lancet Oncol, 9, 777-85.
10. Wong NS, Buckman RA, Clemons M, et al (2010). Phase I/II trial of metronomic chemotherapy with daily Dalteparin and Cyclophosphamide, twice-weekly Methotrexate, and daily prednisone as therapy for metastatic breast cancer Using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol, 28, 723-30.